Servier | search
Click here to view Servier news from 60+ newspapers.
Bookmark or Share- US FDA approves Servier's brain tumor treatment | ReutersServier Pharmaceuticals said on Tuesday the U.S. Food and Drug administration has approved the French drugmaker's treatment for a type of brain tumor, making it the first drug to get a U.S ...
- Home - ServierMaking great strides toward therapeutic progress with Bio-S, Servier’s first bioproduction unit
- Oncology Therapeutics - Servier USServier’s Leadership in Mutant IDH Inhibition. Servier is a leader in oncology driving the science behind targeted mutant isocitrate dehydrogenase (IDH) inhibition.
- About us - ServierServier engages in open innovation to tackle the health challenges facing society, now and in the future. We work fervently alongside our partners, including academic researchers, start-ups, pharmaceutical groups and biotech companies.
- Servier – Our core therapeutic areasSubscribe to email alerts to be informed each time a new article is published on the servier.com website.
More
